

Clinical Diversity Scorecard

Percent of demographic subgroup in the U.S. population based on census data

Drug	
Tradename	
Generic Name	
Company	
Date of FDA Approval	
Indication	FDA approved disease/condition

OVERALL GRADE

A, B, C, D or F based on averaging the demographic subgroup grades



Age



Sex



Race



Ethnicity

Age	% in U.S. Population	% in Clinical Trials	Number treated with new drug	Incidence of Disease or Condition	Grade
≥65 years old	16.5%				

Percent of demographic subgroup enrolled in pivotal trials; Red, yellow and green shading for +/- 30% of population

Sex	% in U.S. Population	Number treated with new drug	Incidence of Disease or Condition	A, B, C, D or F grade for the demographic subgroup representation
Female	50.8%			

Demographic subgroup of interest

Race	% in U.S. Population	% in Clinical Trials	Number of demographic subgroup participants that received the new drug in pivotal trials; Red, yellow and green shading for <30, 30 299, 300+	Incidence of disease or condition	Grade
Black or African	13.4%				
Asian	5.9%				

Ethnicity	% in U.S. Population	% in Clinical Trials	Number treated with new drug	Incidence of disease or condition	Grade
Hispanic or Latino	18.5%				

References: Pivotal Phase 3 studies, FDA review document with demographic page, and references for disease/condition

Increased, similar or decreased risk of the disease/condition in the demographic subgroup based on references